Staff20192020202120222023
Personnel at the end of the year-----
Staff turnover in EUR-----
Turnover LabelEUREUREUREUREUR
The share: stated in EUR20192020202120222023
Shares outstanding (in mn.)53.8453.8453.8453.8453.84
Dividend per share0.770.80.882.171.05
Basic earnings per share1.431.593.892.491.16
P/L in EUR million under IAS/IFRS20192020202120222023
Turnover700.9793.8942.91,024.81,135.4
Operating income (EBIT)120.0136.9298.5243.4170.2
Earnings before taxes111.2126.8292.7229.8113.2
Annual net profit/ loss77.285.8209.6134.262.4
Balance sheet in EUR million under IAS/IFRS20192020202120222023
Assets
Total current assets352.9400.1519.2533.9630.5
Total fixed assets691.9824.3887.7878.91,553.0
Total assets1,044.91,224.41,407.01,412.82,183.5
Liabilities
Total short-term liabilities102.4132.9155.6217.8394.5
Total long-term liabilities647.9757.2742.1653.31,232.3
Total provisions57.0144.8128.989.3117.2
Equity capital284.5324.6499.8532.5545.0
Total liabilities1,044.91,224.41,407.01,412.82,183.5
Management:
Hans-Georg Feldmeier
Andreas Eberhorn
Christof Dreibholz
Karin Samusch
Board:
Wilhelm Beier
Erwin Kern
Lothar Maximilian Lanz
Shareholding in %:
Amundi Asset Management SA (Investment Management) 0.67
Candriam Belgium SA 0.59
Danske Bank A/S (Investment Management) 0.75
Grandeur Peak Global Advisors LLC 1.41
Janus Henderson Investors UK Ltd. 0.90
Lupus alpha Asset Management AG 0.48
Mawer Investment Management Ltd. 3.00
Norges Bank Investment Management 1.18
The Vanguard Group, Inc. 1.14
Wilhelm Beier 67.74
Freefloat 22.14
Address: Lil-Dagover-Ring 7, 82031 Grunwald
T: +49-89-641860
F: +49-89-64186130
I: http://www.dermapharm.de
E: